PL3399962T3 - Kompozycja okulistyczna do leczenia choroby suchego oka - Google Patents

Kompozycja okulistyczna do leczenia choroby suchego oka

Info

Publication number
PL3399962T3
PL3399962T3 PL17832066T PL17832066T PL3399962T3 PL 3399962 T3 PL3399962 T3 PL 3399962T3 PL 17832066 T PL17832066 T PL 17832066T PL 17832066 T PL17832066 T PL 17832066T PL 3399962 T3 PL3399962 T3 PL 3399962T3
Authority
PL
Poland
Prior art keywords
treatment
dry eye
ophthalmic composition
eye disease
ophthalmic
Prior art date
Application number
PL17832066T
Other languages
English (en)
Inventor
Markus Beier
Jörg HAISSER
Alice MEIDES
Sonja KRÖSSER
Hartmut Voss
Frank LÖSCHER
Bernhard GÜNTHER
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of PL3399962T3 publication Critical patent/PL3399962T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/1468Containers characterised by specific material properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06Ampoules or carpules
    • A61J1/067Flexible ampoules, the contents of which are expelled by squeezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17832066T 2016-12-23 2017-12-20 Kompozycja okulistyczna do leczenia choroby suchego oka PL3399962T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16206735 2016-12-23
EP17165578 2017-04-07
PCT/EP2017/083770 WO2018115097A1 (en) 2016-12-23 2017-12-20 Ophthalmic composition for treatment of dry eye disease
EP17832066.9A EP3399962B1 (en) 2016-12-23 2017-12-20 Ophthalmic composition for treatment of dry eye disease

Publications (1)

Publication Number Publication Date
PL3399962T3 true PL3399962T3 (pl) 2021-02-08

Family

ID=61002978

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17832066T PL3399962T3 (pl) 2016-12-23 2017-12-20 Kompozycja okulistyczna do leczenia choroby suchego oka

Country Status (14)

Country Link
US (2) US20180360908A1 (pl)
EP (3) EP3399962B1 (pl)
JP (2) JP7032404B2 (pl)
KR (1) KR102288022B1 (pl)
CN (1) CN110267645A (pl)
AU (1) AU2017384650B2 (pl)
BR (1) BR112019012791A2 (pl)
CA (1) CA3045743C (pl)
DK (1) DK3399962T3 (pl)
ES (2) ES2965883T3 (pl)
MX (1) MX381639B (pl)
PL (1) PL3399962T3 (pl)
PT (1) PT3399962T (pl)
WO (1) WO2018115097A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP3100722B1 (en) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
EP4342537A3 (en) 2012-09-12 2024-07-03 Novaliq GmbH Semifluorinated alkane compositions
AU2014295052B2 (en) 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
EP3356313B1 (en) 2015-09-30 2020-05-06 Novaliq GmbH 2-perfluorohexyl octane for ophthalmic administration
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
PL3515420T3 (pl) 2016-09-22 2024-04-08 Novaliq Gmbh Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3399962B1 (en) 2016-12-23 2020-06-10 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
US12472162B2 (en) * 2018-07-24 2025-11-18 Carefusion 213, Llc Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use
CN112823020A (zh) * 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
EP3975989A1 (en) * 2019-05-24 2022-04-06 Novaliq GmbH Ophthalmic composition for the treatment of ocular allergy
CA3149046A1 (en) * 2019-09-06 2021-03-11 Jorg Haisser Ophthalmic composition for the treatment of uveitis
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
FR2638089A1 (fr) 1988-10-26 1990-04-27 Sandoz Sa Nouvelles compositions ophtalmiques a base d'une cyclosporine
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5578020A (en) 1995-09-01 1996-11-26 Mosley; Manuel L. Drop dispensing apparatus
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5704906A (en) 1996-02-26 1998-01-06 Fox; Richard L. Method of using a topical anesthetic-cleaning solution and applicator
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (pl) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
CA2278328C (en) 1998-02-09 2008-07-22 Macrochem Corporation Antifungal nail lacquer and method using same
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
HK1040195B (zh) 1998-08-19 2006-06-02 Skyepharma Canada Inc. 普鲁泊福的可注射水分散体
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
AU775904B2 (en) 1999-02-08 2004-08-19 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
CN1703206A (zh) 2001-09-04 2005-11-30 泰姆斯多夫药品有限公司 治疗指甲生长功能紊乱失调的膏药
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
AU2003275816A1 (en) 2002-11-13 2004-06-03 Cesar Augusto Cely Lizcano A device and method for facilitating the application of liquid material to the eye
CA2776692C (en) 2003-08-25 2014-12-30 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
US20050175541A1 (en) 2003-11-19 2005-08-11 Lanza Gregory M. Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CA2563544A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
CA2569726A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
KR20070040381A (ko) 2004-07-01 2007-04-16 셰펜스 아이 리써치 눈의 장애 및 상태를 치료하는 조성물 및 방법
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
EP1922060B1 (en) 2005-08-05 2009-01-14 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
AR062046A1 (es) 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
US20080039807A1 (en) 2006-08-08 2008-02-14 Jerrold Scott Pine Ophthalmic Drug Dispensing Tip
EP2068828A2 (en) 2006-09-29 2009-06-17 SurModics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
WO2008070490A2 (en) 2006-11-28 2008-06-12 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
CA2672527A1 (en) 2006-12-07 2008-06-12 Sun Pharma Advanced Research Company Ltd. Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
EP2178502A2 (en) 2007-06-21 2010-04-28 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
AU2009204441B2 (en) 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
EP2110126B9 (de) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
CA2743824A1 (en) 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010127301A1 (en) 2009-05-01 2010-11-04 Allergan, Inc. Method of treating allergic conjunctivitis with cyclosporin compositions
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5549669B2 (ja) 2009-06-25 2014-07-16 ライオン株式会社 眼科用組成物、ドライアイ治療剤及びビタミンaの安定化方法
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
PL2387391T3 (pl) 2009-07-24 2017-09-29 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Sposób otrzymywania ciekłej kompozycji stosowalnej w postaci piany na skórę oraz kompozycja do aplikowania miejscowego
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
MX353154B (es) 2011-01-04 2017-12-20 Novaliq Gmbh Emulsiones de aceite/agua que comprenden alcanos semifluorados.
EP3311802B1 (en) 2011-05-25 2023-11-01 Dermaliq Therapeutics, Inc. Topical pharmaceutical composition based on semifluorinated alkanes
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
CN104066442B (zh) 2012-01-23 2018-05-18 诺瓦利克有限责任公司 基于半氟化烷烃的稳定蛋白质组合物
US9549966B2 (en) * 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) * 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CN110812486A (zh) 2012-07-09 2020-02-21 华柏恩视觉研究中心 用于预防和/或治疗干眼症的组合物、方法和/或装置
EP3100722B1 (en) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
EP4342537A3 (en) 2012-09-12 2024-07-03 Novaliq GmbH Semifluorinated alkane compositions
SG11201503566QA (en) * 2012-12-18 2015-09-29 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
AU2014295052B2 (en) 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
US9265809B2 (en) 2013-10-09 2016-02-23 Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
ES2949040T3 (es) 2014-03-31 2023-09-25 Amcor Rigid Plastics Usa Llc Recipiente de liberación controlada
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
EP3179975B1 (en) * 2014-08-13 2024-12-11 University of Florida Research Foundation, Inc. Preservative removal from eye drops
EA034839B1 (ru) 2014-10-20 2020-03-26 Сентисс Фарма Прайвет Лимитед Офтальмологический раствор
WO2016082644A1 (en) 2014-11-26 2016-06-02 The University Of Hong Kong A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil
EP3356313B1 (en) 2015-09-30 2020-05-06 Novaliq GmbH 2-perfluorohexyl octane for ophthalmic administration
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
WO2017066429A1 (en) 2015-10-14 2017-04-20 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
EP3463344A4 (en) 2016-06-01 2020-02-12 Harold Richard Hellstrom TREATMENT OF DRY EYE WITH PARASYMPATHIC AND ANTISYMPATHIC AGENTS
JP2019520357A (ja) * 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
PL3515420T3 (pl) 2016-09-22 2024-04-08 Novaliq Gmbh Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
CA3036306C (en) * 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US20190328717A1 (en) 2016-12-22 2019-10-31 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
EP3399962B1 (en) 2016-12-23 2020-06-10 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
EP3618782B1 (en) 2017-05-06 2021-05-26 Novaliq GmbH Drop dispenser
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CN111867560B (zh) 2018-03-28 2024-08-13 诺瓦利克有限责任公司 包含噻吗洛尔的药物组合物
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
KR20210080388A (ko) 2018-09-22 2021-06-30 노바리크 게엠베하 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
US12029757B2 (en) 2018-09-27 2024-07-09 Dermaliq Therapeutics, Inc. Lipid barrier repair
CN112823020A (zh) * 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
WO2020109192A1 (en) 2018-11-27 2020-06-04 Novaliq Gmbh Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
US20220008397A1 (en) 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
EP3975989A1 (en) 2019-05-24 2022-04-06 Novaliq GmbH Ophthalmic composition for the treatment of ocular allergy
JP2022543402A (ja) 2019-08-09 2022-10-12 ノバリック ゲーエムベーハー プロスタグランジンアナログを含む局所組成物
CA3149046A1 (en) 2019-09-06 2021-03-11 Jorg Haisser Ophthalmic composition for the treatment of uveitis
EP4065082A1 (en) 2019-11-27 2022-10-05 Novaliq GmbH Suspension comprising a protein particle suspended in a non-aqueous vehicle

Also Published As

Publication number Publication date
US12496326B2 (en) 2025-12-16
KR20190100283A (ko) 2019-08-28
WO2018115097A1 (en) 2018-06-28
CN110267645A (zh) 2019-09-20
ES2965883T3 (es) 2024-04-17
EP3777830B1 (en) 2023-11-29
KR102288022B1 (ko) 2021-08-10
US20180360908A1 (en) 2018-12-20
DK3399962T3 (da) 2020-09-07
AU2017384650A1 (en) 2019-07-04
MX2019007587A (es) 2019-12-16
BR112019012791A2 (pt) 2019-12-03
US20230043641A1 (en) 2023-02-09
WO2018115097A9 (en) 2018-08-23
EP3777830C0 (en) 2023-11-29
PT3399962T (pt) 2020-09-03
EP3399962A1 (en) 2018-11-14
EP4374851A3 (en) 2024-08-21
CA3045743A1 (en) 2018-06-28
JP2022050514A (ja) 2022-03-30
CA3045743C (en) 2023-08-29
EP3399962B1 (en) 2020-06-10
ES2819005T3 (es) 2021-04-14
AU2017384650B2 (en) 2021-02-18
JP2020502197A (ja) 2020-01-23
EP3777830A1 (en) 2021-02-17
EP4374851A2 (en) 2024-05-29
JP7032404B2 (ja) 2022-03-08
MX381639B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
PL3399962T3 (pl) Kompozycja okulistyczna do leczenia choroby suchego oka
SG11202102820VA (en) Ophthalmic composition for treatment of dry eye disease
IL248732A0 (en) Compounds for the treatment of ophthalmological diseases and disorders
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
IL246791A0 (en) Compositions and methods for treating eye diseases
EP3261620A4 (en) Methods and compositions for treating dry eye disease and other eye disorders
HUE066769T2 (hu) Neurodegeneratív szembetegség kezelése pridopidinnal
EP3351219A4 (en) MATERIAL FOR THE OPTICAL TREATMENT OF OCULAR DISEASES
IL267229A (en) Methods of treating ocular disorders
PL3210973T3 (pl) Związki heteroarylowe do leczenia chorób oczu
ES3054066T3 (en) Composition for the treatment of dry eye
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
PL3493823T4 (pl) Składnik na bazie postbiotyki do leczenia zapalenia oka
IL269698B (en) Methods for preventing or treating eye diseases
IL259381B (en) Mirabegron for the treatment of retinal diseases
PL3689341T3 (pl) Gabapentyna okulistyczna do leczenia deepitelializacji rogówki
PL3229780T3 (pl) Kompozycje okulistyczne do zastosowania w leczeniu zespołu suchego oka
GB201910645D0 (en) Treatment for dry eye disease
IL263837A (en) Treatment of ocular disease
SG11202005278PA (en) Compounds for treating eye diseases and methods thereof
ZA201906465B (en) Compositions and methods for treating dry eye diseases
GB201610938D0 (en) Treatment of ocular disease
GB201705435D0 (en) Treatment of ocular disease
AU2016905281A0 (en) Pharmaceutical composition for treatment of an eye disease or condition
AU2016904360A0 (en) Pharmaceutical composition for treatment of an eye disease or condition